{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:07Z","timestamp":1791005887614,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment of myasthenia gravis (MG) has advanced from steroids and traditional immunosuppressants to targeted immunotherapy. Targeted immunotherapy has been successfully employed in clinical practice in recent years. This study aimed to explore the emerging trend of targeted immunotherapy in MG and summarize the knowledge structure through bibliometric methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Web of Science Core Collection database (WoSCC) was chosen to retrieve the literature on targeted immunotherapy for MG. Two bibliometric analysis software, VOSviewer and CiteSpace, and bibliometric online platform were mainly used to evaluate the contributions from countries\/regions, institutions, journals, and authors through the construction and visualization of bibliometric networks. By systematically reviewing a knowledge domain, future research developments were determined. The R version 4.1.2 and Microsoft Excel 365 were used for statistical analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 562 original articles and 262 reviews relevant to MG targeted immunotherapy were included. The number of publications on targeted immunotherapy for MG exhibited a two-phase advancement. The first stage showed a steady growth trend from 1998 to 2016, with an annual number of no more than 35 publications. The second stage revealed an explosive growth trend from 2017, reaching a peak number of publications in 2020. The United States ranked first in the number of publications, citations, and h-index. The author with the highest citation and h-index was Vincent A. And 28.03% of the articles were published in the top 10 journals. In addition to \u201cmyasthenia gravis\u201d, the keyword with the highest consideration was \u201crituximab\u201d, followed by \u201cdouble-blind\u201d, which indicate research hotspots\u00a0gradually from\u00a0basic research\u00a0to\u00a0clinical research over time, especially in the field of targeted immunotherapy. The MG treatment has entered a personalized precision treatment phase. Exploration into\u00a0new\u00a0target molecules\u00a0and conducting high-quality randomized controlled trials on existing biological agents are the further\u00a0research direction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The current study summarized the global research trends concerning targeted immunotherapy for MG. Research interests gradually advanced from basic research to clinical research. MG treatment has entered a personalized precision treatment phase. Further investigations into new target molecules and high-quality randomized controlled trials on existing biological agents are required urgently to direct future immunotherapy research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.998217","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:52:31Z","timestamp":1664445151000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A\u00a0bibliometric\u00a0analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yue","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositive myasthenia gravis: A nationwide epidemiologic study","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2019.8506","article-title":"Steroid side effects","volume":"322","author":"Grennan","year":"2019","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.suppl_2.ii34","article-title":"Advances in targeted therapy: Safety of biological agents","author":"Keystone","year":"2003","journal-title":"Ann Rheum. Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: A double-blinded, randomized, placebo-controlled phase ii study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (Adapt): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007600","article-title":"Randomized phase 2 study of fcrn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40249-016-0182-1","article-title":"Bibliometric study of research and development for neglected diseases in the brics","volume":"5","author":"Bai","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.03.045","article-title":"Bibliometric analysis of global research on pd-1 and pd-L1 in the field of cancer","volume":"72","author":"Gao","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969217","article-title":"Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.587526","article-title":"Open innovation in medical and pharmaceutical research: A literature landscape analysis","volume":"11","author":"Yeung","year":"2020","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.706105","article-title":"Mapping knowledge structure and research frontiers of ultrasound-induced blood-brain barrier opening: A scientometric study","volume":"15","author":"Wu","year":"2021","journal-title":"Front Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184869","article-title":"Publication trends of research on diabetes mellitus and T cells (1997-2016): A 20-year bibliometric study","volume":"12","author":"Gao","year":"2017","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"105243","DOI":"10.1016\/j.aap.2019.07.019","article-title":"Mapping the knowledge domain of road safety studies: A scientometric analysis","volume":"132","author":"Zou","year":"2019","journal-title":"Accid Anal Prev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12376","article-title":"A bibliometric analysis of periodontology","volume":"85","author":"Ahmad","year":"2021","journal-title":"Periodontol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.087","article-title":"Top authors in dermatology by h-index: A bibliometric analysis of 1980-2020","volume":"85","author":"Szeto","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9492LSF","article-title":"Comparison of pubmed, scopus, web of science, and Google scholar: Strengths and weaknesses","volume":"22","author":"Falagas","year":"2008","journal-title":"FASEB J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.561494","article-title":"Bibliometric study of sodium glucose cotransporter 2 inhibitors in cardiovascular research","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.626502","article-title":"Bibliometric analysis of the inflammasome and pyroptosis in brain","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-018-0785-5","article-title":"Bibliometric analysis of global scientific activity on umbilical cord mesenchymal stem cells: A swiftly expanding and shifting focus","volume":"9","author":"Zhao","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00842","article-title":"Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010-2019)","volume":"11","author":"Ke","year":"2020","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11657-021-00929-2","article-title":"Worldwide research tendency and hotspots on hip fracture: A 20-year bibliometric analysis","volume":"16","author":"Wu","year":"2021","journal-title":"Arch Osteoporos."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual's scientific research output","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tree.2008.01.009","article-title":"The h-index and self-citations","volume":"23","author":"Engqvist","year":"2008","journal-title":"Trends Ecol Evol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: Vosviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.787228","article-title":"Mapping knowledge structure and themes trends of osteoporosis in rheumatoid arthritis: A bibliometric analysis","volume":"8","author":"Wu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B34","article-title":"Citespace ii: Visualization and knowledge discovery in bibliographic databases","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"Citespace ii: Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024940629314","article-title":"Bursty and hierarchical structure in streams","volume":"7","author":"Kleinberg","year":"2003","journal-title":"Data Min Knowledge Discovery"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-Cd20 monoclonal antibody: History and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-Pd-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (Regain): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: An analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Info Libr. J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aew264","article-title":"What makes a good systematic review and meta-analysis","volume":"117","author":"M\u00f8ller","year":"2016","journal-title":"Br J Anaesth."},{"key":"B43","doi-asserted-by":"publisher","first-page":"103947","DOI":"10.1016\/j.ijmedinf.2019.08.007","article-title":"Visualizing the intellectual structure and evolution of electronic health and telemedicine research","volume":"130","author":"Gu","year":"2019","journal-title":"Int J Med Inform"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304","article-title":"Igg marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (Adacta): A randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (Fasscinate): A phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-Two-Week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The beatmg study","volume":"98","author":"Nowak","year":"2021","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: A phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/tx800245s","article-title":"The developments and challenges of toxicology education, research, and funding in China","volume":"21","author":"Qu","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7150\/jca.32739","article-title":"Tracking knowledge evolution, hotspots and future directions of emerging technologies in cancers research: A bibliometrics review","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.646311","article-title":"Global research trends of ferroptosis: A rapidly evolving field with enormous potential","volume":"9","author":"Wu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859972","article-title":"Structural and temporal dynamics of mesenchymal stem cells in liver diseases from 2001 to 2021: A bibliometric analysis","volume":"13","author":"Shao","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.815575","article-title":"Knowledge mapping of immunotherapy for hepatocellular carcinoma: A bibliometric study","volume":"13","author":"Shen","year":"2022","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14391","article-title":"Efficacy and safety of rituximab in myasthenia gravis: A French multicentre real-life study","volume":"27","author":"Dos Santos","year":"2020","journal-title":"Eur J Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: A systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27393","article-title":"Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients \u226565 years old","volume":"64","author":"Doughty","year":"2021","journal-title":"Muscle Nerve"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e19416","DOI":"10.7759\/cureus.19416","article-title":"Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in anti-musk positive and anti-achr positive myasthenia gravis","volume":"13","author":"Bastakoti","year":"2021","journal-title":"Cureus"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-achr and anti-musk positive myasthenia gravis patients: A single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J Neurol Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2567.2005.02317.x","article-title":"Imbalance of regulatory T cells in human autoimmune diseases","volume":"117","author":"Dejaco","year":"2006","journal-title":"Immunology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase ii study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in musk myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: Three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and De novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul. Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against b-cells and downstream effectors in generalized autoimmune myasthenia gravis: Current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577528","article-title":"Low-dose rituximab treatment for new-onset generalized myasthenia gravis","volume":"354","author":"Li","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset achr-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.998217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:52:34Z","timestamp":1664445154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.998217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2022.998217"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.998217","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"998217"}}